

1651

I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on the date shown below.

Date: March 19, 2002

By: *Kay L. Saviglio*
Kay L. Saviglio

PATENT
Docket No. GC713

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
Schellenberger et al.)
)
)
Serial No.: 10/022,073)
)
)
Filed: December 13, 2001)
)
For: **TARGETED ENZYMES**)

Group Art Unit: 1651

Examiner: Unassigned

RECEIVED

MAR 31 2003

Supplemental Information Disclosure Statement

TECH CENTER 1600/2900

Commissioner for Patents
Washington, DC 20231

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

The undersigned certifies that:

- ☒ Each item of information contained in the Information Disclosure Statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Those patent(s) or publication(s) which are marked with an asterisk (*) on the attached Form PTO-1449 are not supplied because they were previously cited by or submitted to the Office in a prior application, Serial No. 10/022,097 filed December 13, 2001.

A concise explanation of relevance of the items listed on PTO-1449 is:

- ☒ not given

- ☐ given for each listed item
- ☐ given for only non-English language listed item(s)
- ☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

A copy of the items on Form PTO-1449 is supplied: PCT International Search Report for PCT/US 01/48528, filed December 14, 2001 with attached patents and publications.


☐ each ☒ none ☐ only those listed below:

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,


H. Thomas Anderton, Jr.
Registration No. 40,895

Date: March 19, 2003

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650 846-7544
Fax: 650 845-6504